Request a Rep

For US Healthcare Professionals Only

For you

text alternative goes here

“Wait, What” TV Commercial :60 Seconds

Download this video to play in your office to educate your patients about VUITY®. The video must be played in its entirety and can’t be modified.

Download

text alternative goes here

Access Flashcard

Get highlighted access and
how-to-prescribe information from this handy one-page flashcard.

Download

text alternative goes here

Patient Profiles Flashcard

This flashcard helps you identify appropriate patient types for VUITY®.

Download

UpScript Flashcard Cover with $79 Cost per Vuity Bottle

Access Flashcard

Get highlighted access and
how-to-prescribe information from this handy one-page flashcard.

Download

Flashcard Cover

Patient Profiles Flashcard

This flashcard helps you identify appropriate patient types for VUITY®.

Download

“Wait, What” TV Commercial :60 Seconds

Download this video to play in your office to educate your patients about VUITY™. The video must be played in its entirety and can’t be modified.

Download

UpScript Flashcard Cover with $79 Cost per Vuity Bottle

Access Flashcard

Get highlighted access and
how-to-prescribe information from this handy one-page flashcard.

Download

Flashcard Cover

Patient Profiles Flashcard

This flashcard helps you identify appropriate patient types for VUITY®.

Download

For your patients

Vuity Packaging Illustration

My VUITY® Points (MVP) Flashcard

Help your patients save on VUITY®. Encourage them to enroll.

Download

Cover of Vuity Patient Brochure

Patient Brochure

This brochure helps patients understand presbyopia and how it can be treated.

Download

Eye Chart for Patients

Eye Chart

This eye chart allows patients to evaluate their near vision.

Download

text alternative goes here

UpScript Patient Flashcard

This flashcard provides patients instructions for getting their prescription at home via UpScript Pharmacy.

Download

Frequently asked questions

VUITY^® contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity while maintaining some pupillary response to light.¹ VUITY^® also contracts the ciliary muscle, and may shift the eye to a more myopic state.¹

Please see the results from the GEMINI 1 and GEMINI 2 clinical trials.

Learn more about efficacy

Ready to

take a closer look

at VUITY®?

Request a Rep

Help patients find you

Register or update your information on the Find-a-Doctor tool.

Register now

INDICATION

VUITY® (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

Rare cases of retinal detachment and retinal tear have been reported with miotics, including VUITY. Individuals with pre-existing retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to the initiation of therapy. Patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss.

VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens.

Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.

To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.

ADVERSE REACTIONS

The most common adverse reactions (>5%) reported in clinical trials were headache and conjunctival hyperemia.

Please see full Prescribing Information.

US-VUI-220436

Reference: 1. VUITY [package insert]. North Chicago, IL: AbbVie Inc.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

INDICATION

VUITY® (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults.

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.

Rare cases of retinal detachment and retinal tear have been reported with miotics, including VUITY. Individuals with pre-existing retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to the initiation of therapy. Patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss.

VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens.

Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.

To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.

ADVERSE REACTIONS

The most common adverse reactions (>5%) reported in clinical trials were headache and conjunctival hyperemia.

Please see full Prescribing Information.

US-VUI-220436